Götze, K;Müller-Thomas, C;Peschel, C.The role of azacitidine in the management of myelodysplastic syndromes (MDS)..Cancer Manag. Res..2009.1.119-30

Schlee, M;Roth, A;Hornung, V;Hagmann, CA;Wimmenauer, V;Barchet, W;Coch, C;Janke, M;Mihailovic, A;Wardle, G;Juranek, S;Kato, H;Kawai, T;Poeck, H;Fitzgerald, KA;Takeuchi, O;Akira, S;Tuschl, T;Latz, E;Ludwig, J;Hartmann, G.Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus..Immunity.2009.31.1.25-34

Haas, T;Schmitz, F;Heit, A;Wagner, H.Sequence independent interferon-alpha induction by multimerized phosphodiester DNA depends on spatial regulation of Toll-like receptor-9 activation in plasmacytoid dendritic cells..Immunology.2009.126.2.290-8

Schlee, M;Roth, A;Hornung, V;Hagmann, CA;Wimmenauer, V;Barchet, W;Coch, C;Janke, M;Mihailovic, A;Wardle, G;Juranek, S;Kato, H;Kawai, T;Poeck, H;Fitzgerald, KA;Takeuchi, O;Akira, S;Tuschl, T;Latz, E;Ludwig, J;Hartmann, G.Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus..Immunity.2009.31.1.25-34

Besch, R;Poeck, H;Hohenauer, T;Senft, D;Häcker, G;Berking, C;Hornung, V;Endres, S;Ruzicka, T;Rothenfusser, S;Hartmann, G.Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells..J Clin Invest.2009.119.8.2399-411

Bourquin, C;Schmidt, L;Lanz, AL;Storch, B;Wurzenberger, C;Anz, D;Sandholzer, N;Mocikat, R;Berger, M;Poeck, H;Hartmann, G;Hornung, V;Endres, S.Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7..J Immunol.2009.183.10.6078-86

Ablasser, A;Poeck, H;Anz, D;Berger, M;Schlee, M;Kim, S;Bourquin, C;Goutagny, N;Jiang, Z;Fitzgerald, KA;Rothenfusser, S;Endres, S;Hartmann, G;Hornung, V.Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes..J Immunol.2009.182.11.6824-33

Hochhaus, A;O'Brien, SG;Guilhot, F;Druker, BJ;Branford, S;Foroni, L;Goldman, JM;Müller, MC;Radich, JP;Rudoltz, M;Mone, M;Gathmann, I;Hughes, TP;Larson, RA.Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia..Leukemia.2009.23.6.1054-61

Pirker, R;Pereira, JR;Szczesna, A;von Pawel, J;Krzakowski, M;Ramlau, R;Vynnychenko, I;Park, K;Yu, CT;Ganul, V;Roh, JK;Bajetta, E;O'Byrne, K;de Marinis, F;Eberhardt, W;Goddemeier, T;Emig, M;Gatzemeier, U.Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial..Lancet.2009.373.9674.1525-31

Löwenberg, B;Ossenkoppele, GJ;van Putten, W;Schouten, HC;Graux, C;Ferrant, A;Sonneveld, P;Maertens, J;Jongen-Lavrencic, M;von Lilienfeld-Toal, M;Biemond, BJ;Vellenga, E;Van Marwijk Kooy, M;Verdonck, LF;Beck, J;Döhner, H;Gratwohl, A;Pabst, T;Verhoef, G.High-dose daunorubicin in older patients with acute myeloid leukemia..N Engl J Med.2009.361.13.1235-48